European Commission draft, suggests a non-renewal for Selektope under EU BPR, which now seems as the most likely scenario. Redeye does not find this event surprising, even though we had some hope of a positive outcome. As this process have been known for quite some time and due to the small financial impact, we make no adjustments to estimates or valuation.
LÄS MER
